IMMUNIC, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.22 USD | -3.17% |
|
+3.39% | -18.67% |
| 04-09 | Transcript : Immunic, Inc. - Special Call | |
| 03-21 | Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 110M 8.8B |
|---|---|---|---|---|---|
| Net income 2024 * | -93M -7.44B | Net income 2025 * | -104M -8.33B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 33.12M 2.65B | Net Debt 2025 * | 55.55M 4.45B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.23
x | P/E ratio 2025 * |
-1.23
x | Employees | 77 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.28% |
More Fundamentals
* Assessed data
More news
Latest transcript on Immunic, Inc.
More recommendations
More press releases
More news
| 1 day | -3.17% | ||
| 1 week | +3.39% | ||
| Current month | -7.58% | ||
| 1 month | -6.15% | ||
| 3 months | +6.55% | ||
| 6 months | +15.09% | ||
| Current year | -18.67% |
1 week
1.17
1.31
1 month
1.171.46
Current year
1.091.73
1 year
0.953.11
3 years
0.9515.65
5 years
0.9528.21
10 years
0.9528.99
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Vitt
CEO | Chief Executive Officer | 55 | 31/12/16 |
Glenn Whaley
DFI | Director of Finance/CFO | 56 | 30/11/19 |
Hella Kohlhof
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/12/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Barclay Phillips
BRD | Director/Board Member | 61 | 18/11/19 |
Tamar Howson
BRD | Director/Board Member | 75 | 10/10/19 |
Jörg Neermann
BRD | Director/Board Member | 57 | 31/03/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.22 | -3.17% | 237,436 |
| 25/04/24 | 1.26 | +1.61% | 244,882 |
| 24/04/24 | 1.24 | 0.00% | 129,678 |
| 23/04/24 | 1.24 | +0.81% | 204,479 |
| 22/04/24 | 1.23 | +4.24% | 165,494 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Companyâs s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.22
USD
Average target price
11.5
USD
Spread / Average Target
+842.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.67% | 110M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- IMUX Stock
